

# Christoph Rischpler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5050776/publications.pdf>

Version: 2024-02-01

92  
papers

3,480  
citations

147726

31  
h-index

149623

56  
g-index

92  
all docs

92  
docs citations

92  
times ranked

3519  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2023, 67, .	0.4	8
2	Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. European Heart Journal, 2022, 43, 316-329.	1.0	84
3	Diagnostic Performance of <sup>124</sup> I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma. Journal of Nuclear Medicine, 2022, 63, 869-874.	2.8	8
4	Pitfalls and Common Findings in <sup>68</sup> Ga-FAPI PET: A Pictorial Analysis. Journal of Nuclear Medicine, 2022, 63, 890-896.	2.8	61
5	Visualization of thermal damage using <sup>68</sup> Ga-FAPI-PET/CT after pulmonary vein isolation. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1553-1559.	3.3	9
6	Imaging the Inflammatory Response in Checkpoint Inhibition Myocarditis. Journal of Nuclear Medicine, 2022, 63, 14-16.	2.8	4
7	Cardiac fibroblast activation detected by <sup>68</sup> Gallium-FAPI-46 positron emission tomographyâ€“magnetic resonance imaging as a sign of chronic activity in cardiac sarcoidosis. European Heart Journal - Case Reports, 2022, 6, ytac005.	0.3	13
8	Nuclear Molecular Imaging of Cardiac Remodeling after Myocardial Infarction. Pharmaceuticals, 2022, 15, 183.	1.7	4
9	Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology. International Journal of Molecular Sciences, 2022, 23, 3802.	1.8	3
10	Multiparametric <sup>18</sup> F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers, 2022, 14, 1727.	1.7	20
11	To quantify or not to quantify, that is the question: Semi-quantitative vs. visual analysis of Rb-82 myocardial perfusion imaging PET. Journal of Nuclear Cardiology, 2022, 29, 3163-3165.	1.4	1
12	Clinical Use of PET/MR in Oncology: An Update. Seminars in Nuclear Medicine, 2022, 52, 356-364.	2.5	18
13	Combined PET and MRI for the masses!. Journal of Nuclear Cardiology, 2022, 29, 1518-1519.	1.4	1
14	First experiences with dynamic renal [68Ga]Ga-DOTA-PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3373-3386.	3.3	5
15	Effects of Anti-Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective <sup>scp</sup> Proof-of-Concept Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine. Arthritis and Rheumatology, 2022, 74, 1497-1505.	2.9	6
16	In vivo Visualization of M2 Macrophages in the Myocardium After Myocardial Infarction (MI) Using <sup>68</sup> Ga-NOTA-Anti-MMR Nb: Targeting Mannose Receptor (MR, CD206) on M2 Macrophages. Frontiers in Cardiovascular Medicine, 2022, 9, 889963.	1.1	7
17	Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRIT): A Single-Center Prospective Two-Arm Study. Clinical Cancer Research, 2022, 28, 4194-4202.	3.2	28
18	Safety and Efficacy of <sup>90</sup> Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Clinical Cancer Research, 2022, 28, 4346-4353.	3.2	45

#	ARTICLE	IF	CITATIONS
19	Lung Nodules Missed in Initial Staging of Breast Cancer Patients in PET/MRI—Clinically Relevant?. <i>Cancers</i> , 2022, 14, 3454.	1.7	0
20	EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1040-1069.	3.3	70
21	Evaluation of <sup>18</sup> F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion. <i>Journal of Nuclear Medicine</i> , 2021, 62, 348-353.	2.8	9
22	Multiparametric PET and MRI of myocardial damage after myocardial infarction: correlation of integrin $\alpha$ <sub>v</sub> $\beta$ <sub>3</sub> expression and myocardial blood flow. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1070-1080.	3.3	24
23	Correlation of the apparent diffusion coefficient (ADC) and standardized uptake values (SUV) with overall survival in patients with primary non-small cell lung cancer (NSCLC) using 18F-FDG PET/MRI. <i>European Journal of Radiology</i> , 2021, 134, 109422.	1.2	4
24	Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1016-1039.	3.3	62
25	First Experience Using <sup>18</sup> F-Fluorobenguanine PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 479-485.	2.8	5
26	Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 170-177.	2.5	55
27	<sup>68</sup> Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1235-1241.	2.8	39
28	Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision. <i>BMC Cancer</i> , 2021, 21, 62.	1.1	16
29	Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer. <i>EJNMMI Physics</i> , 2021, 8, 14.	1.3	11
30	Imaging Inflammation with Positron Emission Tomography. <i>Biomedicines</i> , 2021, 9, 212.	1.4	24
31	Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision. <i>EJNMMI Research</i> , 2021, 11, 21.	1.1	10
32	Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3141-3150.	3.3	23
33	Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1399-1413.	3.3	45
34	Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC. <i>Cancers</i> , 2021, 13, 1728.	1.7	7
35	Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid 68Ga-DOTATOC PET/MRI. <i>European Journal of Radiology</i> , 2021, 137, 109588.	1.2	5
36	Evaluation of the Predictive Potential of 18F-FDG PET and DWI Data Sets for Relevant Prognostic Parameters of Primary Soft-Tissue Sarcomas. <i>Cancers</i> , 2021, 13, 2753.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Comparison of pre- and post-contrast-enhanced attenuation correction using a CAIPI-accelerated T1-weighted Dixon 3D-VIBE sequence in 68Ga-DOTATOC PET/MRI. <i>European Journal of Radiology</i> , 2021, 139, 109691.	1.2	4
38	Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding. <i>Cancers</i> , 2021, 13, 2928.	1.7	34
39	N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard. <i>EJNMMI Research</i> , 2021, 11, 68.	1.1	2
40	Fabry Cardiomyopathy: Current Treatment and Future Options. <i>Journal of Clinical Medicine</i> , 2021, 10, 3026.	1.0	8
41	Initial clinical experience with <sup>90</sup> Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262468.	2.8	64
42	Imaging pheochromocytoma in small animals: preclinical models to improve diagnosis and treatment. <i>EJNMMI Research</i> , 2021, 11, 121.	1.1	3
43	Atypical bilateral ventilation/perfusion mismatches in an asymptomatic patient suffering from metastatic thyroid cancer. <i>European Journal of Hybrid Imaging</i> , 2021, 5, 25.	0.6	1
44	Cardiac fibroblast activation detected by positron emission tomography/computed tomography as a possible sign of cardiotoxicity. <i>European Heart Journal</i> , 2020, 41, 1060-1060.	1.0	41
45	Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma – a case report. <i>International Journal of Hyperthermia</i> , 2020, 37, 55-65.	1.1	8
46	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1037-1042.	2.8	19
47	Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: a joint collaboration of the EACVI and the EANM: A summary. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 1320-1330.	0.5	35
48	18F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET?. <i>Journal of Clinical Medicine</i> , 2020, 9, 3163.	1.0	9
49	Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3074-3083.	3.3	9
50	<p></p>Diagnosis and Screening of Patients with Fabry Disease</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 551-558.	0.9	37
51	SNMMI Procedure Standard/EANM Guideline for Gated Equilibrium Radionuclide Angiography*. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 126-135.	0.4	14
52	Molecular Imaging and Therapy of Colorectal and Anal Cancer. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 465-470.	2.5	6
53	Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2020, 41, 363-369.	0.5	16
54	Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [18F]FDG PET/CT and [18F]FDG PET/MRI. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 183-191.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Cardiac PET/MRI: Current Clinical Status and Future Perspectives. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 260-269.	2.5	12
56	Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from <sup>68</sup> Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. <i>BMC Cancer</i> , 2020, 20, 326.	1.1	38
57	Imaging inflammation after myocardial infarction: implications for prognosis and therapeutic guidance. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 35-50.	0.4	3
58	<sup>18</sup> F-fluciclovine PET-CT and <sup>68</sup> Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , The, 2019, 20, 1286-1294.	5.1	338
59	What is the best PET target for early biochemical recurrence of prostate cancer?â€œAuthorsâ€™ reply. <i>Lancet Oncology</i> , The, 2019, 20, e609-e610.	5.1	4
60	EANM procedural guidelines for myocardial perfusion scintigraphy using cardiac-centered gamma cameras. <i>European Journal of Hybrid Imaging</i> , 2019, 3, 11.	0.6	46
61	Artificial Intelligence in Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2019, 60, 29S-37S.	2.8	95
62	A compressed sensing accelerated radial MS-CAIPIRINHA technique for extended anatomical coverage in myocardial perfusion studies on PET/MR systems. <i>Physica Medica</i> , 2019, 64, 157-165.	0.4	4
63	PET/MR Imaging in Cardiovascular Imaging. <i>PET Clinics</i> , 2019, 14, 233-244.	1.5	11
64	Assessment of <sup>68</sup> Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	3.4	493
65	Monocyte-platelet aggregates affect local inflammation in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 287, 7-12.	0.8	15
66	Efficacy, Predictive Factors, and Prediction Nomograms for <sup>68</sup> Ga-labeled Prostate-specific Membrane Antigenâ€œligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 656-661.	0.9	129
67	<sup>68</sup> Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1406-1411.	2.8	106
68	Expression and Cellular Localization of CXCR4 and CXCL12 in Human Carotid Atherosclerotic Plaques. <i>Thrombosis and Haemostasis</i> , 2018, 118, 195-206.	1.8	43
69	Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM). <i>European Radiology</i> , 2018, 28, 4086-4101.	2.3	80
70	Myocardial perfusion quantification using simultaneously acquired <sup>13</sup> NH <sub>3</sub> â€œmonna PET and dynamic contrast-enhanced MRI in patients at rest and stress. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 2641-2654.	1.9	35
71	Cardiovascular imaging in cardio-oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S4351-S4366.	0.6	13
72	Motion-corrected whole-heart PET-MR for the simultaneous visualisation of coronary artery integrity and myocardial viability: an initial clinical validation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1975-1986.	3.3	27

#	ARTICLE	IF	CITATIONS
73	Detection Efficacy of Hybrid <sup>68</sup> Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1081-1087.	2.8	66
74	<sup>68</sup> Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	2.8	111
75	PET/MR: Yet another Tesla?. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1019-1031.	1.4	13
76	Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer <sup>68</sup> Ga-Pentixafor for PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 499-506.	2.8	94
77	Measurement of extracellular volume and transit time heterogeneity using contrast-enhanced myocardial perfusion MRI in patients after acute myocardial infarction. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 2320-2330.	1.9	14
78	Cardiovascular preclinical imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 48-59.	0.4	6
79	Prospective Evaluation of <sup>18</sup> F-Fluorodeoxyglucose Uptake in Postischemic Myocardium by Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging as a Prognostic Marker of Functional Outcome. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004316.	1.3	107
80	PET/MR Imaging in Heart Disease. <i>PET Clinics</i> , 2016, 11, 465-477.	1.5	8
81	Sympathetic nerve damage and restoration after ischemia-reperfusion injury as assessed by <sup>11</sup> C-hydroxyephedrine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 312-318.	3.3	14
82	Acute myocardial infarction. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 60, 236-51.	0.4	13
83	B-lymphoblastic lymphoma: a heartening diagnosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 116-116.	0.5	2
84	PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmural vs. <sup>18</sup> F-FDG uptake. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 661-9.	0.5	84
85	Retention Kinetics of the <sup>18</sup> F-Labeled Sympathetic Nerve PET Tracer LMI1195: Comparison with <sup>11</sup> C-Hydroxyephedrine and <sup>123</sup> I-MIBG. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1429-1433.	2.8	66
86	Current and Future Status of PET Myocardial Perfusion Tracers. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.4	3
87	Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: implications for diagnosis, monitoring and treatment. <i>European Heart Journal</i> , 2014, 35, 312-312.	1.0	66
88	Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1077-1083.	3.3	21
89	Hybrid PET/MR Imaging of the Heart: Potential, Initial Experiences, and Future Prospects. <i>Journal of Nuclear Medicine</i> , 2013, 54, 402-415.	2.8	144
90	PET/MR imaging of atherosclerosis: initial experience and outlook. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 393-6.	1.0	16

#	ARTICLE	IF	CITATIONS
91	Transient Ischemic Dilation Ratio in <sup>82</sup> Rb PET Myocardial Perfusion Imaging: Normal Values and Significance as a Diagnostic and Prognostic Marker. Journal of Nuclear Medicine, 2012, 53, 723-730.	2.8	40
92	Advances in PET myocardial perfusion imaging: F-18 labeled tracers. Annals of Nuclear Medicine, 2012, 26, 1-6.	1.2	42